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Background: The progression and geographical 
distribution of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infection in the United 
Kingdom (UK) and elsewhere is unknown because 
typically only symptomatic individuals are diagnosed. 
We performed a serological study of blood donors in 
Scotland in the spring of 2020 to detect neutralising 
antibodies to SARS-CoV-2 as a marker of past infec-
tion and epidemic progression. Aim: Our objective 
was to determine if sera from blood bank donors can 
be used to track the emergence and progression of 
the SARS-CoV-2 epidemic. Methods: A pseudotyped 
SARS-CoV-2 virus microneutralisation assay was used 
to detect neutralising antibodies to SARS-CoV-2. The 
study comprised samples from 3,500 blood donors 
collected in Scotland between 17 March and 18 May 
2020. Controls were collected from 100 donors in 
Scotland during 2019. Results: All samples collected 
on 17 March 2020 (n = 500) were negative in the pseu-
dotyped SARS-CoV-2 virus microneutralisation assay. 
Neutralising antibodies were detected in six of 500 
donors from 23 to 26 March. The number of samples 
containing neutralising antibodies did not signifi-
cantly rise after 5–6 April until the end of the study on 
18 May. We found that infections were concentrated in 
certain postcodes, indicating that outbreaks of infec-
tion were extremely localised. In contrast, other areas 
remained comparatively untouched by the epidemic.
Conclusion: Although blood donors are not represent-
ative of the overall population, we demonstrated that 
serosurveys of blood banks can serve as a useful tool 
for tracking the emergence and progression of an epi-
demic such as the SARS-CoV-2 outbreak. 
Introduction
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) emerged in late 2019 in Hubei province, 
China as a cause of respiratory disease occasionally 
leading to coronavirus disease (COVID-19) [1,2]. Older 
age, male sex, smoking and comorbidities such as 
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cardiac disease, hypertension and diabetes have been 
identified as risk factors for severe infections [3,4].
Symptomatic individuals typically exhibit fever, cough 
and shortness of breath 2–14 days after infection [5]. 
However, an unknown proportion of individuals experi-
ence no symptoms [6-8]. Antibody responses in both 
symptomatic and asymptomatic individuals are detect-
able in the blood 14–28 days after infection [9,10]. 
Subsequently, antibody levels drop and can become 
undetectable by some antibody assays in the early 
convalescent phase [9,11,12].
In this study, we used blood donors as a means of 
estimating population exposure from the start of the 
pandemic in March through to mid-May when PCR-
detected cases in the United Kingdom (UK) had pla-
teaued [13,14]. The detection frequency of neutralising 
antibodies in blood donors and a discussion of its 




We analysed six batches of 500 plasma samples col-
lected on 17 March, 21–23 March, 5–6 April, 18–20 
April, 2–4 May and 16–18 May from Scotland. Each 
batch was sampled from a range of health boards across 
Scotland, with the coverage varying between batches. 
An additional 500 samples from the Greater Glasgow 
region, collected between 2 and 4 May were also ana-
lysed. This yielded a total of 3,500 post-pandemic 
blood donor samples. Of these samples, 53.4% were 
from female donors. The median age of donors was 47 
years (IQR: 34–56); children under 16 years are not per-
mitted to donate blood. As negative controls, we tested 
in parallel 100 blood donor samples from the Scottish 
National Blood Transfusion Service (SNBTS) anony-
mous archive collected between September 2018 and 
December 2019 (IRAS project number 18005), before 
the first reports of the spread of SARS-CoV-2 in China 
[1,2]. Seventeen control samples from contract-traced 
individuals who were PCR-confirmed as SARS-CoV-2 
infected were used as positive controls in the study. 
All the individuals from whom the positive control sera 
samples were taken had asymptomatic SARS-CoV-2 
infections and were recruited through the International 
Severe Acute Respiratory and Emerging Infection 
Consortium (ISARIC) World Health Organization Clinical 
Characterisation Protocol UK (CCP-UK) at the time point 
of discharge plus 28 days. Samples were heat-inacti-
vated before serological testing by incubation at 56 °C 
for 30 min.
SARS-CoV-2 pseudotype microneutralisation 
assay
A lentivirus-based SARS-CoV-2 pseudovirus parti-
cle was constructed displaying the full spike protein 
on the surface of the pseudotyped virus using a syn-
thetic codon-optimised SARS-CoV-2 expression con-
struct (NCBI reference sequence: YP_009724390.1). 
Virus infectivity was determined by titration on HEK 
293T ACE2-plasmid-transfected cells as previously 
described [15]. Neutralisation titres are expressed as 
50% inhibitory concentration (IC50) values. During the 
assay, plates were barcoded and controls were periodi-
cally added to the runs. Laboratory staff were blinded 
regarding the arrangement of positive controls periodi-
cally added to the assay plates.
Titration
Pre-pandemic samples and samples collected on 17 
March and 21–23 March were all titrated to optimise 
the neutralisation assay. After this point, samples were 
initially screened for neutralisation using the highest 
1:20 dilution. Dilutions of 1:20 were performed in tripli-
cate along with virus only, no virus and positive control 
wells. Samples that produced a mean RLU two stand-
ard deviations below the mean RLU of all the samples 
on the plate were then titrated out to obtain IC50 values.
Enzyme-linked immunosorbent assay
Antibodies to the trimeric spike protein were detected 
by ELISA. MAXISORP immunoplates (442404; NUNC; 
Merck, Darmstadt, Germany) were coated with 
StrepMAB-Classic (2–1507–001; IBA Life Sciences, 
Göttingen, Germany). Plates were blocked with 2% 
skimmed milk in phosphate buffered saline (PBS) for 
1 h and then incubated with 0.125 μg of soluble SARS-
CoV-2 trimeric spike protein or 2% skimmed milk in 
PBS. After 1 h, plasma was added at 1:50 dilution, fol-
lowed by alkaline phosphatase (AP)-conjugated anti-
human IgG (A9544; Merck, Darmstadt, Germany) at 
Figure 1
Selection criteria for classifying a sample as SARS-CoV-2-
neutralising, Scotland, March–May 2020 (n = 3,617)
No dilution response: n = 1,927
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ELISA: enzyme-linked immunosorbent assay; IC50: 50% inhibitory 
concentration; SARS-CoV-2: severe acute respiratory syndrome 
coronavirus 2.
Samples are required to have an estimated IC50 and a standard 
error at least as small as the worst-neutralising positive 
control. This penalises samples with poorly defined inhibitory 
concentrations. Pre-pandemic samples are shown in yellow, 
positive controls in red and blood donor samples in blue. ELISA 
results are annotated as + or − on the points.
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1:10,000 dilution or AP-conjugated anti-human IgM 
(A9794; Merck, Darmstadt, Germany) at 1:5,000 dilu-
tion. The reaction was developed by the addition of 
p-nitrophenyl phosphate (PNPP, Merck, Darmstadt, 
Germany) substrate and stopped with NaOH. The 
absorbance was measured at 405 nm after 1 h. Further 
information is provided in Adams et al. [16].
Estimating the 50% inhibitory concentration
The RLU for each well were standardised against tech-
nical positive (cells and virus without serum) and neg-
ative (cells without serum or virus) controls on each 
plate to determine a percentage neutralisation value. 
We calculated an average neutralisation across the 
two sample replicates on each plate (for each dilu-
tion). Dilution curves were fit to each sample, with the 
percentage neutralisation modelled as a logistic func-
tion of the dilution factor. This yielded an IC50  value 
Figure 2
SARS-CoV-2 antibody prevalence estimates for each health board through time using the model outlined in the methods, 
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a Poor sample coverage and single positive result for the estimates for Forth Valley could be fit by a range of values.
Filled circles: median prevalence estimates, colour denoting sample size; thick and thin error bars: 90 and 95% highest density intervals, 
respectively. Red diamonds: raw percentage estimates from the data.
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for each sample where a curve could be fit; samples 
that showed no dilution response because of complete 
or no neutralisation were not given an IC50        value. 
Dilution curves were estimated using nonlinear least 
squares in R version 3.6.3 [17]. An error-weighted mean 
of the IC50 value was calculated for samples that were 
repeated on more than one plate. We classified positive 
samples as having an IC50 value greater than the largest 
negative control (1:69) with a standard error less than 
or equal to the least neutralising positive control.
Determining test sensitivity and specificity
Test sensitivity (probability of neutralisation in a given 
positive serum) and specificity (probability of a nega-
tive result given no exposure) was estimated using 17 
(RT-PCR-confirmed) positive controls and 100 pre-pan-
demic blood donor samples as negative controls. The 
highest IC50  observed for a negative control was used 
as a threshold to determine positive samples (giving 
100% specificity; 95% credible interval (CI): 98.10–
100; n = 117). Of the 17 positive controls, 16 samples 
neutralised with high confidence, giving an estimated 
sensitivity of 94.11% (95% CI: 79.17–99.98).
Accounting for sensitivity and specificity in 
sample prevalence estimates
Uncertainty in test sensitivity and specificity can be 
propagated to sample prevalence estimates using a 
simple hierarchical Bayesian model [18]. The number 
of positive tests in the positive (n+ = 16) and negative 
(n− = 0) control groups was modelled as a binomial 
distribution:
where the sensitivity is given by π+ and the specificity 
by π− (N + = 17 and N − = 100 are the number of positive 
and negative controls, respectively). An estimate of 
the true proportion of positive sera for samples from a 
given week and health board (pw,h ) comprises neutral-
ising sera that were missed ([1 − π+]) and those incor-
rectly identified as neutralising samples (from [1 − π−]). 
The observed number of positive samples for the week 
w and health board h (nw,h) was modelled as a binomial 
distribution accounting for test performance:
with  Nw,h  the number of samples from each health 
board in each week. Using this method, the uncertainty 
in test specificity and sensitivity is propagated to the 
estimate of the seroprevalence; this results in broader 
credible intervals that better reflect the inherent uncer-
tainty in test parameters.
Modelling sample prevalence
In estimating seroprevalence, we assumed that neu-
tralising antibodies did not wane in the blood donor 
population during the survey period and accrued to 
an equilibrium [12]. Making this assumption, we can 
fit the logistic function to the time series of sample 
seroprevalence:
Here, θ  h  is the equilibrium seroprevalence, ρ  h  is the 
rate with which the seroprevalence approaches this 
maximum and τ  h  is the midpoint of the logistic curve 
for each health board. Parameters were modelled using 
hierarchical distributions across health boards (the 
maximum as a beta to bound it between 0 and 1, the 
Figure 3
Estimates of SARS-CoV-2 antibody prevalence at the 
end of our study period (the parameter θ h from the 
logistic equation), ordered by the lower 95% highest 



















































































Blue points: median parameter estimate; thick and thin error 
bars: 90 and 95% highest density intervals, respectively. All 
sample estimates are characterised by high uncertainty: the 
Lanarkshire health board was predicted to have the highest 
prevalence; Greater Glasgow and Clyde were estimated with the 
most confidence, while Forth Valley, Borders and Highland could 
not be interpreted and estimates for the Forth Valley should be 
treated with scepticism because of poor sampling (see Figure 2).
a Poor sample coverage and single positive result for the estimates 
for Forth Valley could be fit by a range of values.
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Figure 4
Health boards showing estimated endpoint seroprevalences for SARS-CoV-2 in blood donors, Scotland, March–May 2020 
(n = 3,500)
White health boards were not sufficiently sampled to generate estimates. The colour scale denotes the confidence and seroprevalence in each 
health board. Labels give estimated blood donor seroprevalence for the health board with associated 95% highest density intervals.
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rate and the midpoint as a normal distribution). Priors 
are given in the  Supplementary material. The model 
was fit in R version 3.6.3 using the Bayesian infer-
ence package JAGS version 4.3.0 [19]. Models were run 
across six chains until convergence (potential scale 
reduction factor less than 1.02 and effective sample 
size > 10,000).
Ethical statement
Ethical approval was obtained for the SNBTS anony-
mous archive - IRAS project number 18005. SNBTS 
blood donors gave fully informed consent to viro-
logical testing, donation was made under the SNBTS 
Blood Establishment Authorisation and the study 
was approved by the SNBTS Research and Sample 
Governance Committee.
Results
The estimated IC50  values and standard errors for the 
control and blood donor samples are shown in  Figure 
1. Of the 3,500 post-pandemic blood donor samples, 
a total of 111 contained anti-SARS-CoV-2 neutralising 
antibodies using the IC50  and standard error-based 
thresholds described in the Methods. The results of 
the neutralisation assay were positively correlated 
with ELISA optical density (Supplementary Figure S2; 
Pearson’s correlation coefficient = 0.86; p < 0.001).
No samples from 17 March showed neutralising activ-
ity. Blood donor samples obtained from donations 
during 21–23 March, 5–6 April, 18–20 April, 2–4 May 
and 16–18 May contained neutralising anti-SARS-
CoV-2 antibodies (Figure 2). The number of samples 
Figure 5
Raw counts of positive SARS-CoV-2 samples in the additional survey of postcodes close to Glasgow, blood donors, March–
May 2020 (n = 490)
490 samples fell within districts adjacent to the city.
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containing neutralising antibodies did not rise signifi-
cantly after 5–6 April.
Estimates of seroprevalence in the healthcare boards, 
based on the final sampling point between the 16–18 
May, are illustrated in  Figures 3  and  4. The lowest 
uncertainty was associated with estimates from the 
Greater Glasgow and Clyde health board (5.35%; 95% 
highest density interval (HDI): 3.19–7.89); Tayside, 
Lothian and Grampian had similar median estimates 
with higher uncertainty. Lanarkshire was predicted to 
have the highest seroprevalence of all health boards 
(7.59%; 95% HDI: 4.60–11.20) while the Highlands 
and Borders had the lowest seroprevalence of around 
2.08 (95% HDI: 0–5.08) and 2.16 (95% HDI: 0–5.85), 
respectively. Throughout this period, IC50  values did 
not show a statistically significant difference between 
weeks (Supplementary Figure S3). No statistically sig-
nificant variation in IC50 value was seen based on age 
or sex (Supplementary Figure S4).
The outbreaks as a whole in Scotland were con-
centrated in the major urban centres, Glasgow and 
Edinburgh, and the Lanarkshire health authority region 
(Figures 3 and 4). To explore this phenomenon further, 
we performed a separate analysis of 490 samples from 
the Greater Glasgow region collected between 18 and 
20 April. Of these 490 samples, 42 had neutralising 
antibodies. Analysis of the distribution of samples con-
taining neutralising antibodies by postcodes showed 
that most of these samples located in the Paisley 
(14/85) and Motherwell (15/197) postcodes of Greater 
Glasgow, indicating that outbreaks in the city and its 
surrounding localities are localised. By comparison, 
Central Glasgow had comparatively few samples con-
taining neutralising antibodies (7/195; Figure 5).
Discussion
Our study strengthens existing evidence that blood 
donors can be used as a sentinel population to track 
the emergence and progression of an epidemic.
While the demographics of blood donors differ in 
several aspects from the general population, most 
notably because of the exclusion of those at risk for 
blood-borne viruses (HIV, hepatitis B and C virus) and 
syphilis, they might be considered a reasonable repre-
sentation of the adult population in the absence of any 
obvious predisposing factors for infection. The only 
other general exclusions were a 4-week and a 4-month 
donation deferral period in those people who travelled 
to specified countries at risk for arbovirus and malaria 
infections, respectively.
However, estimates of seroprevalence are complicated 
by non-uniform sampling. The blood donations col-
lected and tested in this study were focused in spe-
cific postcodes, based on the locations where weekly 
donations took place. This produces an added level 
of complexity as our data showed that outbreaks are 
focused in specific communities even on the scale of 
a medium-sized city such as Glasgow. This is further 
confounded by the absence of samples from individu-
als younger than 18 and older than 75 years.
The results presented in this study are based on a 
formally not validated assay. However, by using con-
tact-traced asymptomatic individuals who had been 
PCR-confirmed as infected by SARS-CoV-2 and 100 
blood donations obtained before the epidemic, we 
were able to ascertain the sensitivity of the assay. 
Furthermore, a second ELISA was used to confirm the 
analysis. As this assay detected 16 of 17 PCR-confirmed 
asymptomatic cases, we estimated its sensitivity at 
94.11% (95% CI: 79.17–99.98). Other studies have pre-
viously shown that the pMN assay correlates well with 
other laboratory-based and commercial serological 
assays [20].
Our assay is designed to be specific for SARS-CoV-2. 
There are four seasonal coronaviruses, HKU1, OC43, 
NL63 and 229E, which circulate during the winter 
months [21]. The 100 pre-pandemic samples collected 
in the winter months of 2019 will have been from donors 
previously infected with seasonal coronaviruses (but 
not SARS-CoV-2). By setting the cut-off for our assay 
above the highest IC50  value observed in the 100 pre-
pandemic samples, we ensured the specificity of the 
assay and can have a high degree of confidence that 
the antibodies detected in the samples from March to 
May 2020 were generated by SARS-CoV-2 infection. The 
utility of using pMN assays and ELISA to track popula-
tion exposure is dependent on the assumptions (i) that 
every infected individual seroconverts and (ii) that once 
seroconverted, the antibodies remain circulating in the 
blood at detectable levels. A decrease in total antibody 
and neutralising antibody titres has been noted in sam-
ples drawn up to 2 months after the peak neutralising 
antibody response (ca 3–4 weeks after infection). In 
some instances, antibody levels become undetectable 
when tested with a specific assay and analysis meth-
odology [9,12]. This drop in titres may lead to false 
negatives in the later time points. However, the dates 
of collection used in this study all fell within 3 months 
of the diagnosis of the first confirmed case in Scotland 
on 1 March [22]. For this reason, it is unlikely that this 
study is hampered by a drop in neutralising antibody 
levels, although future seroprevalence studies may 
potentially underestimate the true level of population 
exposure. In addition, some individuals may not sero-
convert, representing a small pool of false negative 
patients [11].
Conclusion
Samples containing anti-SARS-CoV-2 neutralising 
antibodies were detected in blood donors who gave 
blood between 16 and 17 March 2020 in all Scottish 
health boards. Subsequently, samples containing anti-
SARS-CoV-2 neutralising antibodies were detected 
at every further time point assayed until the end of 
the study. Consequently, considering the 14–28 day 
incubation period before seroconversion, it is likely 
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that SARS-CoV-2 began circulating in Scotland in late 
February 2020 and potentially earlier.
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